hydroxyurea has been researched along with Colonic Neoplasms in 38 studies
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) in combination with hydroxyurea (HU) or 2'-deoxyguanosine (GdR) on human gastric carcinoma MK-1 cells and colon carcinoma HT-15 cells was studied." | 7.68 | Synergistic inhibition of human gastric carcinoma cell growth by 1-beta-D-arabinofuranosylcytosine and hydroxyurea or 2'-deoxyguanosine in vitro. ( Kamiguchi, H; Kawahara, T; Matsumoto, M; Ohkubo, T; Tsuda, M; Yamamura, M, 1992) |
| "It remains elusive whether aneuploidy affects the drug sensitivity of hydroxyurea." | 5.51 | p53 mediates hydroxyurea resistance in aneuploid cells of colon cancer. ( Fang, X; Fu, Y; Liu, Y; Wu, F; Yin, H; Yu, D; Zhang, H; Zong, L, 2019) |
| "In a randomized, multicenter study, 168 evaluable patients with colorectal adenocarcinoma at B2, C1 or C2 stages of the Dukes, Astler and Coller classification, were treated after radical surgery with BCG and 5-fluorouracil alone (regimen A) or in combination with hydroxyurea, methyl-CCNU and mitomycin C (regimen B)." | 5.05 | Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma. ( De Vecchis, L; Lagomarsino Caprino, MC; Mazzei, T; Periti, P; Popoli, P, 1984) |
| "The cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) in combination with hydroxyurea (HU) or 2'-deoxyguanosine (GdR) on human gastric carcinoma MK-1 cells and colon carcinoma HT-15 cells was studied." | 3.68 | Synergistic inhibition of human gastric carcinoma cell growth by 1-beta-D-arabinofuranosylcytosine and hydroxyurea or 2'-deoxyguanosine in vitro. ( Kamiguchi, H; Kawahara, T; Matsumoto, M; Ohkubo, T; Tsuda, M; Yamamura, M, 1992) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "It remains elusive whether aneuploidy affects the drug sensitivity of hydroxyurea." | 1.51 | p53 mediates hydroxyurea resistance in aneuploid cells of colon cancer. ( Fang, X; Fu, Y; Liu, Y; Wu, F; Yin, H; Yu, D; Zhang, H; Zong, L, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (34.21) | 18.7374 |
| 1990's | 13 (34.21) | 18.2507 |
| 2000's | 7 (18.42) | 29.6817 |
| 2010's | 4 (10.53) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Suetsugu, T | 1 |
| Mori, R | 1 |
| Futamura, M | 1 |
| Fukada, M | 1 |
| Tanaka, H | 1 |
| Yasufuku, I | 1 |
| Sato, Y | 1 |
| Iwata, Y | 1 |
| Imai, T | 1 |
| Imai, H | 1 |
| Tanaka, Y | 1 |
| Okumura, N | 1 |
| Matsuhashi, N | 1 |
| Takahashi, T | 1 |
| Yoshida, K | 1 |
| Fang, X | 1 |
| Yin, H | 1 |
| Zhang, H | 3 |
| Wu, F | 1 |
| Liu, Y | 1 |
| Fu, Y | 1 |
| Yu, D | 1 |
| Zong, L | 1 |
| Saban, N | 1 |
| Stepanić, V | 1 |
| Vučinić, S | 1 |
| Horvatić, A | 1 |
| Cindrić, M | 1 |
| Perković, I | 1 |
| Zorc, B | 1 |
| Oršolić, N | 1 |
| Mintas, M | 1 |
| Pavelić, K | 1 |
| Pavelić, SK | 1 |
| Gounaris, E | 1 |
| Heiferman, MJ | 1 |
| Heiferman, JR | 1 |
| Shrivastav, M | 1 |
| Vitello, D | 1 |
| Blatner, NR | 1 |
| Knab, LM | 1 |
| Phillips, JD | 1 |
| Cheon, EC | 1 |
| Grippo, PJ | 1 |
| Khazaie, K | 1 |
| Munshi, HG | 1 |
| Bentrem, DJ | 1 |
| Vigneron, AM | 1 |
| Vousden, KH | 1 |
| Li, Y | 1 |
| Xie, M | 1 |
| Hu, M | 1 |
| Ge, S | 1 |
| Yang, D | 1 |
| Wan, Y | 1 |
| Yan, B | 1 |
| Biard, DS | 1 |
| Miccoli, L | 1 |
| Despras, E | 1 |
| Harper, F | 1 |
| Pichard, E | 1 |
| Créminon, C | 1 |
| Angulo, JF | 1 |
| Lin, ZP | 1 |
| Belcourt, MF | 1 |
| Cory, JG | 1 |
| Sartorelli, AC | 1 |
| Huang, XW | 1 |
| Tang, ZY | 1 |
| Lawrence, TS | 1 |
| Zhang, M | 1 |
| Wu, D | 1 |
| Chen, B | 1 |
| Parihar, K | 1 |
| He, L | 1 |
| Fan, C | 1 |
| Zhang, J | 1 |
| Liu, L | 1 |
| Gillis, A | 1 |
| Bruce, A | 1 |
| Kapoor, A | 1 |
| Tang, D | 1 |
| Engstrom, PF | 3 |
| MacIntyre, JM | 3 |
| Mittelman, A | 2 |
| Klaassen, DJ | 1 |
| Lagomarsino Caprino, MC | 1 |
| Mazzei, T | 1 |
| De Vecchis, L | 1 |
| Popoli, P | 1 |
| Periti, P | 1 |
| Kao, AK | 1 |
| Muggia, FM | 2 |
| Dubin, N | 1 |
| Lerner, WA | 1 |
| Stark, R | 1 |
| Wernz, JC | 1 |
| Speyer, JL | 1 |
| Blum, RH | 1 |
| Liberati, AM | 1 |
| Di Costanzo, F | 1 |
| Buzzi, F | 1 |
| Fatati, G | 1 |
| Biscottini, B | 1 |
| Ballatori, E | 1 |
| Falchi, R | 1 |
| Grignani, F | 1 |
| Douglass, HO | 2 |
| Muggia, F | 1 |
| Hussey, HJ | 1 |
| Tisdale, MJ | 1 |
| Wadler, S | 4 |
| Horowitz, R | 2 |
| Rao, J | 1 |
| Mao, X | 1 |
| Schlesinger, K | 1 |
| Schwartz, EL | 3 |
| Makower, D | 1 |
| Haynes, H | 1 |
| Zhang, HY | 1 |
| Hirano, T | 1 |
| Shiraishi, K | 1 |
| Adachi, K | 1 |
| Miura, S | 1 |
| Watanabe, H | 1 |
| Utiyama, H | 1 |
| Smith, TA | 2 |
| Titley, JC | 1 |
| Lamb, JR | 1 |
| Goehle, S | 1 |
| Ludlow, C | 1 |
| Simon, JA | 1 |
| Boucher, PD | 1 |
| Ostruszka, LJ | 1 |
| Murphy, PJ | 1 |
| Shewach, DS | 1 |
| Krein, BM | 1 |
| Conroy, JF | 1 |
| Brodsky, I | 1 |
| Lokich, JJ | 1 |
| Pitman, SW | 1 |
| Skarin, AT | 1 |
| Chiu, CS | 1 |
| Chan, AK | 1 |
| Wright, JA | 1 |
| Matsumoto, M | 1 |
| Kawahara, T | 1 |
| Tsuda, M | 1 |
| Ohkubo, T | 1 |
| Kamiguchi, H | 1 |
| Yamamura, M | 1 |
| Moran, RG | 1 |
| Bagshawe, KD | 1 |
| Sharma, K | 1 |
| Southall, PJ | 1 |
| Boden, JA | 1 |
| Boxer, GM | 1 |
| Patridge, TA | 1 |
| Antoniw, P | 1 |
| Pedley, RB | 1 |
| Swinnen, LJ | 1 |
| Ellis, NK | 1 |
| Erickson, LC | 1 |
| Schutt, AJ | 1 |
| Robichaud, NJ | 1 |
| Fram, RJ | 1 |
| Seidel, HJ | 1 |
| Ariel, IM | 1 |
| Slack, NM | 1 |
| Jones, R | 1 |
| Connors, TA | 1 |
1 review available for hydroxyurea and Colonic Neoplasms
| Article | Year |
|---|---|
Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Hy | 1992 |
5 trials available for hydroxyurea and Colonic Neoplasms
| Article | Year |
|---|---|
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Ne | 1984 |
Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275).
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration | 1982 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
Topics: Anemia; Asparaginase; Azaserine; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug | 1970 |
32 other studies available for hydroxyurea and Colonic Neoplasms
| Article | Year |
|---|---|
Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2021 |
p53 mediates hydroxyurea resistance in aneuploid cells of colon cancer.
Topics: Aneuploidy; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Drug Resistance | 2019 |
Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model.
Topics: Amino Acids; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Cycle Checkpoints; Cell | 2013 |
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Topics: Animals; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Hydroxyurea; Inflammatory Bowel | 2015 |
An indirect role for ASPP1 in limiting p53-dependent p21 expression and cellular senescence.
Topics: Acyltransferases; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Apoptosis Regulatory Protein | 2012 |
Abundant expression of Dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation.
Topics: Adenocarcinoma; Adult; Amino Acid Sequence; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; | 2002 |
Participation of kin17 protein in replication factories and in other DNA transactions mediated by high molecular weight nuclear complexes.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Division; Co | 2003 |
Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxyribonucle | 2004 |
5-fluorouracil and hydroxyurea enhance adenovirus-mediated transgene expression in colon and hepatocellular carcinoma cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; beta-Galactosidase; Carcinoma, | 2005 |
ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function.
Topics: 3T3 Cells; Animals; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle Proteins; C | 2006 |
Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; | 1984 |
5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Hyd | 1983 |
Inhibition of tumour growth by lipoxygenase inhibitors.
Topics: Adenocarcinoma; Administration, Oral; Analysis of Variance; Animals; Benzeneacetamides; Cell Divisio | 1996 |
Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: effects in wild-type and resistant human colon cancer cells.
Topics: Base Sequence; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Humans; | 1996 |
Micropreparation of cultured cells for in situ reverse transcription PCR.
Topics: Cell Culture Techniques; Colonic Neoplasms; DNA Primers; Gene Expression Regulation, Neoplastic; His | 1997 |
Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.
Topics: Antineoplastic Agents; Blood Platelets; Clinical Trials as Topic; Colonic Neoplasms; Endothelial Gro | 1997 |
Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells.
Topics: Cell Cycle; Cell Division; Colonic Neoplasms; Deoxyribonucleotides; Fluorouracil; G1 Phase; Gene Exp | 1998 |
Co-localization of mitochondrial and double minute DNA in the nuclei of HL-60 cells but not normal cells.
Topics: Cell Cycle; Cell Nucleus; Cell Transformation, Neoplastic; Colonic Neoplasms; DNA Damage; DNA, Mitoc | 1999 |
Hydroxyurea treatment enhances metastatic cell adhesiveness: a possible chemotherapy-induced increase in metastatic potential?
Topics: Antineoplastic Agents; Cell Adhesion; Colonic Neoplasms; Humans; Hydroxyurea; Neoplasm Metastasis; T | 1999 |
Uptake of glucose analogues by colonic tumour cells during growth and after treatment with hydroxyurea.
Topics: 3-O-Methylglucose; Cell Division; Colonic Neoplasms; Deoxyglucose; DNA; Flow Cytometry; Humans; Hydr | 1999 |
Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Chickens; CHO Cells; Colonic Neoplasms | 2001 |
Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy.
Topics: Animals; Antimetabolites; Antiviral Agents; Aphidicolin; Bystander Effect; Cell Cycle; Cell Line; Co | 2002 |
Sequential 5-fluorouracil and hydroxyurea therapy for metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Hydroxyurea; Neoplasm Metastasis; Rectal Ne | 1978 |
Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
Topics: Administration, Oral; Ataxia; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointe | 1975 |
Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II).
Topics: Animals; Cell Division; Cisplatin; Colonic Neoplasms; Drug Resistance; Escherichia coli; Female; Hum | 1992 |
Synergistic inhibition of human gastric carcinoma cell growth by 1-beta-D-arabinofuranosylcytosine and hydroxyurea or 2'-deoxyguanosine in vitro.
Topics: Carcinoma; Cell Death; Cell Division; Colonic Neoplasms; Cytarabine; Deoxyguanosine; Deoxyribonucleo | 1992 |
Selective uptake of toxic nucleoside (125IUdR) by resistant cancer.
Topics: Adenocarcinoma; Animals; Cell Line; Choriocarcinoma; Colon; Colonic Neoplasms; Cytarabine; Drug Resi | 1991 |
Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)-induced DNA interstand cross-link removal and potentiation of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) cytotoxicity by hydroxyurea and 1-beta-D-arabinofuranosylcytosine.
Topics: Animals; Carboplatin; Cell Survival; Colonic Neoplasms; Cytarabine; DNA Repair; DNA, Neoplasm; Drug | 1991 |
Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells.
Topics: Aphidicolin; Cell Line; Cell Survival; Colonic Neoplasms; Cytarabine; Diterpenes; DNA; Drug Resistan | 1987 |
[Estimation of tumor sensitivity in vitro. II. Studies with the solid Ehrlich carcinoma of the mouse and the GW 77, a heterotransplanted human carcinoma].
Topics: Animals; Antibiotics, Antineoplastic; Autoradiography; Carcinoma; Carcinoma, Ehrlich Tumor; Colonic | 1970 |
Anticancer therapy with hydrea: comparative study of daily vs. intermittent oral dosage.
Topics: Administration, Oral; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Dr | 1974 |
An outline of cancer chemotherapy.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Asparaginase; Breast Neoplasms; | 1971 |